Search clinical trials for: mFOLFOXIRI + Cadonilimab

Total 170 results

Gruppo Oncologico del Nord-Ovest

Completed

FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer (TRIP)

Metastatic Colo-rectal Cancer

Italy
Sixth Affiliated Hospital, Sun Yat-sen University

Not yet recruiting

Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Rectal Cancer | Chemotherapy Effect
Peking University Third Hospital

Not yet recruiting

AK104 Combined With I-125 Brachytherapy for Recurrent or Metastatic Cervical Cancer

Cervical Cancer
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer

Locally Advanced Colorectal Carcinoma

China
Fudan University

Recruiting

IV Ascorbic Acid in Peritoneal Metastatic Colorectal Cancer

Colorectal Cancer | Vitamin C | GLUT3

China
Li Zhang

Recruiting

Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Neoadjuvant Therapies

China
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Cervical Cancer | Fertility Preservation | Radical Hysterectomy | Neoadjuvant Chemoimmunotherapy

China
Gruppo Oncologico del Nord-Ovest

Completed

Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient (MACBETH)

Metastatic Colorectal Cancer

Italy
Peking University

Unknown

mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial

Advanced Esophageal Carcinoma

China
Sun Yat-sen University
Akeso; Haplox Biotechnology Co., Ltd.

Recruiting

Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Shenzhen People's Hospital
Sixth Affiliated Hospital, Sun Yat-sen University; The University of Hong Kong-Shenzhen...

Recruiting

Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer (NeoCaCRT)

Locally Advanced Rectal Carcinoma

China
Sun Yat-sen University
Guangzhou Burning Rock Dx Co., Ltd.

Recruiting

MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer (MIRROR)

Colorectal Cancer

China
Sun Yat-sen University

Not yet recruiting

Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy

Colorectal Cancer
Stanford University

Active, not recruiting

Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer

Rectal Cancer

United States
Zhejiang Cancer Hospital

Recruiting

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

HER2 Gene Mutation | Bile Duct Adenocarcinoma Non-Resectable

China
Rutgers, The State University of New Jersey

Recruiting

sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

Gastro-Intestinal Cancer

United States
RemeGen Co., Ltd.

Recruiting

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

Locally Advanced Unresectable Gastric Adenocarcinoma

China
Guangxi Medical University

Not yet recruiting

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Immune Checkpoint Inhibitors
Cancer Institute and Hospital, Chinese Academy...

Recruiting

XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

Rectal Cancer | MSS

China
University of Utah
Pfizer

Completed

A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

Advanced KRAS Positive Metastatic Colorectal Cancer

United States
Shanghai Zhongshan Hospital
Sun Yat-sen University; Eastern Hepatobiliary Surgery Hospital

Not yet recruiting

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Hepatocellular Carcinoma

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Gastric Cancer | Esophagogastric Junction Cancer

China
West China Hospital
GeneCast Biotechnology Co., Ltd.

Recruiting

ctDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial) (REVISE)

Colon Cancer

China
Hanoi Medical University

Completed

Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI

Colorectal Cancer

Vietnam
University of Utah

Terminated

Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer (IPOX-FOLFIRI)

Colorectal Cancer | Peritoneal Carcinoma | Appendiceal Cancer

United States
Sun Yat-sen University

Recruiting

Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

Colon Cancer Stage II | Colon Cancer Stage III

China
Zhongnan Hospital
Akeso Biopharma Co., Ltd.

Recruiting

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Cervical Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Shanxi Province Cancer Hospital

Recruiting

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Muscle Invasive Bladder Carcinoma

China
Xuekui Liu

Recruiting

Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma (NCCCNRHNSCC)

Head and Neck Squamous Cell Carcinoma | Locally Advanced Operable

China
Peking University

Unknown

mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus

Advanced Esophageal Carcinoma

China
Peking Union Medical College Hospital

Recruiting

Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma

Cadonilimab and Lenvatinib

China
Sun Yat-sen University

Recruiting

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Clear Cell Renal Cell Carcinoma | Neoadjuvant Therapy | Cadonilimab

China
First Affiliated Hospital of Zhejiang University

Unknown

Neoadjuvant mFOLFOXIRI Chemotherapy Alone for Extramural Vascular Invasion Positive Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Sun Yat-sen University

Recruiting

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Hepatocellular Carcinoma | Pulmonary Metastases | Bevacizumab | Liver Cancer Stage IV | Cryoablation | Cadonilimab

China
Tianjin Medical University Cancer Institute and...

Recruiting

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

China
Sun Yat-sen University

Recruiting

Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation

Rectal Cancer

China
Health Science Center of Xi'an Jiaotong University

Recruiting

Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer (GCR-05)

Cervical Cancer

China
AIO-Studien-gGmbH
Amgen; ClinAssess GmbH

Completed

FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) (VOLFI)

Metastatic Colorectal Cancer

Germany
West China Hospital

Recruiting

Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer

Cholangiocarcinoma Non-resectable

China
Fudan University

Recruiting

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Microsatellite Stable Colorectal Carcinoma | RAS Mutation | Cadonilimab

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC

Pancreatic Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Enrolling by invitation

Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Rectal Cancer

Gastrointestinal Neoplasms | Intestinal Neoplasms | Rectal Diseases | Rectal Neoplasms | Lymph Node Metastasis | Oxaliplatin | Cancer of Rectum and Anus

China
West China Hospital

Not yet recruiting

Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer

Gastric Cancer
Akeso

Not yet recruiting

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric and Gastroesophageal Junction Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy...
Akeso Pharmaceuticals, Inc.

Not yet recruiting

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Metastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
Xijing Hospital

Not yet recruiting

An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC

Gastric Cancer

China
Chinese University of Hong Kong

Active, not recruiting

Colon Neoadjuvant FOLFOXIRI Study

Rectal Cancer

Hong Kong
Women's Hospital School Of Medicine Zhejiang University
Akeso

Not yet recruiting

Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors

Cervical Cancer | Uterine Cervical Neoplasms | Cancer of Cervix | Uterine Cervical Cancer | Cervical Neoplasms | Cancer of the Uterine Cervix
Yonsei University

Recruiting

A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer

Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy | Unresectable Metastatic Right-sided Colon Cancer, Stage IV

Korea, Republic of

Search clinical trials for: mFOLFOXIRI + Cadonilimab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations